Hepatitis B virus-associated diffuse large B-cell lymphoma: Unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin

Oncotarget

Volumn 6, Issue 28, 2015, Pages 25061-25075

  Deng, Lijuan ^a   Song, Yuqin ^a   Young, Ken H ^b   Hu, Shimin ^b   Ding, Ning ^a   Song, Weiwei ^a   Li, Xianghong ^a   Shi, Yunfei ^a   Huang, Huiying ^a   Liu, Weiping ^a   Zheng, Wen ^a   Wang, Xiaopei ^a   Xie, Yan ^a   Lin, Ningjing ^a   Tu, Meifeng ^a   Ping, Lingyan ^a   Ying, Zhitao ^a   Zhang, Chen ^a   Sun, Yingli ^a   Zhu, Jun ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

B cell receptor; Complementarity determining region 3; Diffuse large B cell lymphoma; Hepatitis B surface antigen; Hepatitis B virus

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; ANTINEOPLASTIC AGENT; HEPATITIS B ANTIBODY; IMMUNOGLOBULIN VARIABLE REGION;

ADULT; AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ARTICLE; CHINA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENE MUTATION; HEPATITIS B; HUMAN; HUMAN CELL; IGHV GENE; IGLV GENE; IMMUNOGLOBULIN GENE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SPLEEN; SURVIVAL RATE; ADOLESCENT; AGED; B LYMPHOCYTE; CANCER STAGING; CHILD; COMPLICATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFECTS; EPIDEMIOLOGY; HEPATITIS B VIRUS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MORTALITY; PATHOGENICITY; PATHOLOGY; PREVALENCE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CHILD; CHINA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN VARIABLE REGION; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84944455696     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4677     Document Type: Article

References (43)

1. Nowoslawski A, Brzosko WJ, Madalinski K, Krawczynski K. Cellular localisation of Australia antigen in the liver of patients with lymphoproliferative disorders. Lancet. 1970; 1:494-498.
2. Heimann R, Ray MB, Desmet VJ. HBsAg, chronic lymphoproliferative disorders, and cirrhosis of liver. Journal of clinical pathology. 1977; 30:817-821.
3. Kim JH, Bang YJ, Park BJ, Yoo T, Kim CW, Kim TY, Heo DS, Lee HS, Kim NK. Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study. Japanese journal of cancer research: Gann. 2002; 93:471-477.
4. Crook PD, Jones ME, Hall AJ. Mortality of hepatitis B surface antigen-positive blood donors in England and Wales. International journal of epidemiology. 2003; 32:118-124.
5. Ulcickas Yood M, Quesenberry CP, Jr., Guo D, Caldwell C, Wells K, Shan J, Sanders L, Skovron ML, Iloeje U, Manos MM. Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection. Hepatology. 2007; 46:107-112.
6. Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. The Lancet Oncology. 2010; 11:827-834.
7. Fwu CW, Chien YC, You SL, Nelson KE, Kirk GD, Kuo HS, Feinleib M, Chen CJ. Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of parous women in Taiwan. Hepatology. 2011; 53:1217-1225.
8. Nath A, Agarwal R, Malhotra P, Varma S. Prevalence of hepatitis B virus infection in non-Hodgkin lymphoma: a systematic review and meta-analysis. Internal medicine journal. 2010; 40:633-641.
9. Dalia S, Chavez J, Castillo JJ, Sokol L. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies. Leukemia research. 2013; 37:1107-1115.
10. Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood. 2011; 117:1792-1798.
11. Vannata B, Zucca E. Hepatitis C virus-associated B-cell non-Hodgkin lymphomas. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2014; 2014:590-598.
12. Marcucci F, Spada E, Mele A, Caserta CA, Pulsoni A. The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma -a review. American journal of blood research. 2012; 2:18-28.
13. Kusumoto S, Tobinai K. Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2014; 2014:576-583.
14. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, et al. Reprint of: Epidemiological serosurvey of Hepatitis B in China-declining HBV prevalence due to Hepatitis B vaccination. Vaccine. 2013; 31:J21-28.
15. Lu FM, Zhuang H. Management of hepatitis B in China. Chinese medical journal. 2009; 122:3-4.
16. European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. Journal of hepatology. 2012; 57:167-185.
17. Lim ST, Fei G, Quek R, Lim LC, Lee LH, Yap SP, Loong S, Tao M. The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis. European journal of haematology. 2007; 79:132-137.
18. Wang F, Xu RH, Luo HY, Zhang DS, Jiang WQ, Huang HQ, Sun XF, Xia ZJ, Guan ZZ. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC cancer. 2008; 8:115.
19. Xie W, Zhou D, Hu K, Xiao X, Huang W, He J, Shi J, Luo Y, Zhang J, Lin M, Cai Z, Huang H, Ye X. Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy. Experimental and therapeutic medicine. 2013; 6:109-114.
20. Wei Z, Zou S, Li F, Cheng Z, Li J, Wang J, Wang C, Chen F, Cao J, Cheng Y. HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospectie analysis in China. Medcine oncology. 2014; 31:845.
21. Wang F, Xu RH, Han B, Shi YX, Luo HY, Jiang WQ, Lin TY, Huang HQ, Xia ZJ, Guan ZZ. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer. 2007; 109:1360-1364.
22. Law MF, Lai HK, Chan HN, Ha CY, Nq C, Yeung YM, Yip SF. The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma. European Journal of Cancer Care. 2015; 24:117-124.
23. Chen J, Wang J, Yang J, Zhang W, Song X, Chen L. Concurrent infection of hepatitis B virus negatively affects the clinical outcome and prognosis of patients with non-Hodgkin's lymphoma after chemotherapy. PloS one. 2013; 8:e69400.
24. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103:275-282.
25. Zinzani PL. The many faces of marginal zone lymphoma. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2012; 2012:426-432.
26. Bikos V, Darzentas N, Hadzidimitriou A, Davis Z, Hockley S, Traverse-Glehen A, Algara P, Santoro A, Gonzalez D, Mollejo M, Dagklis A, Gangemi F, Bosler DS, Bourikas G, Anagnostopoulos A, Tsaftaris A, et al. Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia. 2012; 26:1638-1646.
27. Kraj P, Friedman DF, Stevenson F, Silberstein LE. Evidence for the overexpression of the VH4-34 (VH4.21) Ig gene segment in the normal adult human peripheral blood B cell repertoire. Journal of immunology. 1995; 154:6406-6420.
28. Sebastian E, Alcoceba M, Balanzategui A, Marin L, Montes-Moreno S, Flores T, Gonzalez D, Sarasquete ME, Chillon MC, Puig N, Corral R, Pardal E, Martin A, Gonzalez-Barca E, Caballero MD, San Miguel JF, et al. Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigendriven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype. The American journal of pathology. 2012; 181:1879-1888.
29. Baptista MJ, Calpe E, Fernandez E, Colomo L, Cardesa-Salzmann TM, Abrisqueta P, Bosch F, Crespo M. Analysis of the IGHV region in Burkitt's lymphomas supports a germinal center origin and a role for superantigens in lymphomagenesis. Leukemia research. 2014; 38:509-515.
30. Smilevska T, Tsakou E, Hadzidimitriou A, Bikos V, Stavroyianni N, Laoutaris N, Fassas A, Alphanagnostopoulos A, Papadaki T, Belessi C, Stamatopoulos K. Immunoglobulin kappa gene repertoire and somatic hypermutation patterns in follicular lymphoma. Blood cells, molecules & diseases. 2008; 41:215-218.
31. Mockridge CI, Rahman A, Buchan S, Hamblin T, Isenberg DA, Stevenson FK, Potter KN. Common patterns of B cell perturbation and expanded V4-34 immunoglobulin gene usage in autoimmunity and infection. Autoimmunity. 2004; 37:9-15.
32. Pugh-Bernard AE, Silverman GJ, Cappione AJ, Villano ME, Ryan DH, Insel RA, Sanz I. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. The Journal of clinical investigation. 2001; 108:1061-1070.
33. Bikos V, Stalika E, Baliakas P, Darzentas N, Davis Z, Traverse-Glehen A, Dagklis A, Kanellis G, Anagnostopoulos A, Tsaftaris A, Ponzoni M, Berger F, Felman P, Ghia P, Papadaki T, Oscier D, et al. Selection of antigen receptors in splenic marginal-zone lymphoma: further support from the analysis of the immunoglobulin lightchain gene repertoire. Leukemia. 2012; 26:2567-2569.
34. Zhu D, Lossos C, Chapman-Fredricks JR, Lossos IS. Biased immunoglobulin light chain use in the Chlamydophila psittaci negative ocular adnexal marginal zone lymphomas. American journal of hematology. 2013; 88:379-384.
35. Hadzidimitriou A, Agathangelidis A, Darzentas N, Murray F, Delfau-Larue MH, Pedersen LB, Lopez AN, Dagklis A, Rombout P, Beldjord K, Kolstad A, Dreyling MH, Anagnostopoulos A, Tsaftaris A, Mavragani-Tsipidou P, Rosenwald A, et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood. 2011; 118:3088-3095.
36. Pighi C, Barbi S, Bertolaso A, Zamo A. Mantle cell lymphoma cell lines show no evident immunoglobulin heavy chain stereotypy but frequent light chain stereotypy. Leukemia & lymphoma. 2013; 54:1747-1755.
37. Hadzidimitriou A, Darzentas N, Murray F, Smilevska T, Arvaniti E, Tresoldi C, Tsaftaris A, Laoutaris N, Anagnostopoulos A, Davi F, Ghia P, Rosenquist R, Stamatopoulos K, Belessi C. Evidence for the significant role of immunoglobulin light chains in antigen recognition and selection in chronic lymphocytic leukemia. Blood. 2009; 113:403-411.
38. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. The New England journal of medicine. 2004; 350:1118-1129.
39. Chen MH, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Teng HW, Wang WS, Chao TC, Yen CC, Chen PM. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma. Annals of hematology. 2008; 87:475-480.
40. Chan CH, Hadlock KG, Foung SK, Levy S. V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood. 2001; 97:1023-1026.
41. Van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, Garcia-Sanz R, van Krieken JH, Droese J, Gonzalez D, Bastard C, White HE, Spaargaren M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003; 17:2257-2317.
42. Giudicelli V, Brochet X, Lefranc MP. IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harbor protocols. 2011; 2011:695-715.
43. De Re V, De Vita S, Marzotto A, Rupolo M, Gloghini A, Pivetta B, Gasparotto D, Carbone A, Boiocchi M. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factorproducing cells that occur mainly in type II cryoglobulinemia. Blood. 2000; 96:3578-3584.